An interventional study of collection in Obesity, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Screening
Pouget M, Pinel A, Miolanne M, Gentes E, Picard M, Martinez R, Mulliez A, Guillet C, Farigon N, Boirie Y. Improving the functional detection of sarcopenic obes…PubMed 39467062 ↗
Among 44 studies in Obesity by University Hospital, Clermont-Ferrand — 6 open to participants now, 6 under way, none of them phase 3. Obesity · University Hospital, Clermont-Ferrand.
Among the 44 studies in Obesity by University Hospital, Clermont-Ferrand, this one is the 3rd largest by enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2018, is one of 34 with no phase, and was the 18th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
Browse Obesity studies →6 of the 44 studies in Obesity by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–90
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–80
University Hospital, Clermont-Ferrand · Sites in France
Ages 1 days–4 yrs · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–40 · Women only
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–60 · Women only
By country, each count listing its studies:
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 799 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Median enrollment 40 across the 37 interventional studies, 90 across the 7 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 179 are open to participants now.
1 of the studies in Obesity by University Hospital, Clermont-Ferrand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07120685University Hospital, Clermont-FerrandProof of Concept in the Prevention of Post-bariatric Sarcopenia: Simulated Activation of the "Gravitostat" | 2027-11 |
Among the 44 studies in Obesity by University Hospital, Clermont-Ferrand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims first to determine the prevalence of sarcopenia in a population of obese people of extended age group (18-70 years). In a second step, the factors determining and / or predisposing to sarcopenic obesity will be identified as well as plasmatic and urinary biomarkers specific to this phenotype.
Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
Biological collection to identify plasma, serum, genetic, urinary and faecal biomarkers associated with sarcopenic obesity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
Other: collection
Blood, urinary and faecal samples
Sarcopenia
The primary endpoint is sarcopenia (present / absent), defined using the muscle mass index (SMI) corresponding to = SM / Height², where the total muscle mass (SM) is calculated from validated equations. by Janssen et al in a population of men and women with a large age range (18-86 years) and adiposity (BMI: 16-48 kg / m integrating bio-impedancemetry data ( BIA).
Time frame: at day 1
Ran from Jun 2018 to primary completion in Apr 2022, 46 months.
Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 46 months is above that.
Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jun 2020 → Apr 2022 and completion Jun 2020 → Apr 2022.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Pouget M, Pinel A, Miolanne M, Gentes E, Picard M, Martinez R, Mulliez A, Guillet C, Farigon N, Boirie Y. Improving the functional detection of sarcopenic obes…PubMed 39467062 ↗
Pouget M, Pinel A, Miolanne M, Gentes E, Picard M, Martinez R, Mulliez A, Guillet C, Farigon N, Boirie Y. Improving the functional detection of sarcopenic obes…PubMed 39467062 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →